Midatech Pharma PLC (MTP)

[BioSpecialist]

This undiscovered and massive underpriced stock is a must have for everyone who likes Biotech . Big News coming in April like the market launch of Zuplenz and the Phase 2 results of their Oral thin-film Insulin which targets a $20+ Billion Market .


Neil Woodford Buys More ‘Profoundly Undervalued’ Allied Minds PLC, 4d Pharma PLC And Midatech Pharma PLC
http://www.iii.co.uk/articles/303418/neil-woodford-buys-more-%E2%80%98profoundly-undervalued%E2%80%99-allied-minds-plc-4d-pharma-plc-and-?context=LSE:MTPH

Midatech Pharma

Index: FTSE AIM All-Share -- Share price: 156.5p -- Market cap: £52.4m -- Proportion of company owned by Woodford Asset Management: 20.0%

Nanomedicine company Midatech Pharma had net assets of £37.1m at 30 June 2015, so the shares are trading at 1.4 times NAV, which compares favourably with 4d Pharma's 8.3 times NAV.

Midatech also boasts some revenues, having brought in £0.4m over the 12 months to 30 June. A leap to over £8m is forecast for calendar 2016, with around £14m currently pencilled in for 2017 -- which would give a not-outrageous P/S ratio of 3.7 at the current share price.